ArticleFrontiers in drug delivery2025
Poor-tasting pediatric medicines: part 2. Exploring caregiver and healthcare provider values and preferences for a novel taste-blocker product to improve acceptability.
Article in Frontiers in drug delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Poor-tasting pediatric medicines: Part 1. A scoping review of their impact on patient acceptability, medication adherence, and treatment outcomes.Frontiers in drug delivery · 2025Pooled it
- Maternal Practices and Knowledge on Mixing Pediatric Medications with Food: Evidence of Counseling Gaps and Educational Needs in Primary Care.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Improving the palatability of bitter-tasting medication for pediatric populations has long presented a challenge. Taste blockers are being researched as a potential solution; however, end-user perspectives and needs related to this concept have not been explored. The objectives of this research were 1) to understand current experiences of administering bitter-tasting medication; 2) the evaluation of a consumer-targeted product profile (CTPP) for a taste blocker including attributes such as form and duration of action; and 3) whether there is a need to support improved acceptability and adherence with a taste blocker taken before the bitter-tasting medication. Methods: Our study consisted of simultaneous qualitative and quantitative phases, involving caregivers and healthcare providers with experience administering medications to children aged 2-17 years. Qualitative research was conducted with 120 caregivers and 92 healthcare providers using a range of methods. Focus groups (FGs) were conducted in Kenya, Nigeria and Zimbabwe (grouped as Sub-Saharan Africa (SSA) but not intended to be representative of the region as a whole) with caregivers of children who had taken medication for HIV, TB, pneumonia, or malaria (including for seasonal prevention) within the past 6 months. Telephone in-depth interviews (TDIs) were conducted with caregivers of children with chronic illnesses in the United States. Face-to-face in-depth interviews (IDIs) and TDIs were conducted with healthcare providers. The quantitative part of the study was conducted with n = 1,815 caregivers and n = 859 healthcare providers using face-to-face computer-assisted interviews (CAPI) in SSA, and Results: Participants described how bitter-tasting medications create challenges in multiple areas: for caregivers, children, their daily life and routines, healthcare providers, and children's perceptions of healthcare. In SSA, 28.9% of caregivers reported that their children Conclusion: The results of the study indicate that there is a high perceived need for a taste blocker to aid in administering bitter-tasting pediatric medication. Concerns around duration and potential impact of long-term use must be addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.